434 related articles for article (PubMed ID: 20580896)
1. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
Ouwerkerk J; Boers-Doets C
Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
3. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Patel DK
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
[TBL] [Abstract][Full Text] [Related]
4. Administration of anti-EGFR therapy: a practical review.
Khoukaz T
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):20-7. PubMed ID: 16616283
[TBL] [Abstract][Full Text] [Related]
5. Review of panitumumab: a targeted therapy.
Winkeljohn DL
Clin J Oncol Nurs; 2008 Feb; 12(1):30-2. PubMed ID: 18258571
[No Abstract] [Full Text] [Related]
6. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
Dunsford J
Clin J Oncol Nurs; 2008 Jun; 12(3):405-7. PubMed ID: 18515238
[No Abstract] [Full Text] [Related]
7. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
10. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer.
Grothey A
Oncology (Williston Park); 2006 Dec; 20(14 Suppl 10):21-8. PubMed ID: 17354514
[TBL] [Abstract][Full Text] [Related]
11. Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.
Morse L
ONS News; 2006; 21(8 Suppl):59-60. PubMed ID: 16925155
[No Abstract] [Full Text] [Related]
12. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
[TBL] [Abstract][Full Text] [Related]
13. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
You B; Chen EX
J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
[TBL] [Abstract][Full Text] [Related]
14. Integration of panitumumab into the treatment of colorectal cancer.
Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
[TBL] [Abstract][Full Text] [Related]
15. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
Heun J; Holen K
Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
[TBL] [Abstract][Full Text] [Related]
16. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
[TBL] [Abstract][Full Text] [Related]
18. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?
Peeters M; Price T; Van Laethem JL
Oncologist; 2009 Jan; 14(1):29-39. PubMed ID: 19144681
[TBL] [Abstract][Full Text] [Related]
19. Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials.
Bauer KA; Hammerman S; Rapoport B; Lacouture ME
Clin Colorectal Cancer; 2008 Sep; 7(5):309-14. PubMed ID: 18794062
[TBL] [Abstract][Full Text] [Related]
20. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada.
Pettigrew M; Kavan P; Surprenant L; Lim HJ
J Med Econ; 2016; 19(2):135-47. PubMed ID: 26442575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]